Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Shannon L RisacherLiana G Apostolova

Abstract

We investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET). Forty-four participants (18 cognitively normal older adults [CN], 10 mild cognitive impairment, 16 Alzheimer's disease [AD]) underwent amyloid PET and a blood draw. Free and total plasma Aβ40 and Aβ42 were assessed using a validated assay. Thirty-seven participants (17 CN, 8 mild cognitive impairment, 12 AD) also underwent a [18F]flortaucipir scan. Scans were preprocessed by standard techniques, and mean global and regional amyloid and tau values were extracted. Free Aβ42/Aβ40 (Aβ F42:F40) and total Aβ42/Aβ40 (Aβ T42:T40) were evaluated for differences by diagnosis and relation to PET Aβ positivity. Relationships between these measures and cerebral Aβ and tau on both regional and voxel-wise basis were also evaluated. Lower Aβ T42:T40 was associated with diagnosis and PET Aβ positivity. Lower plasma Aβ T42:T40 ratios predicted cerebral Aβ positivity, both across the full sample and in CN only. Finally, lower plasma Aβ T42:T40 ratios were associated with increased cortical Aβ and tau in AD-related regions on both regional and voxel-wise analyses. Plasma Aβ measures may be useful biomarkers for...Continue Reading

References

Dec 20, 1996·The Journal of Biological Chemistry·A L BiereD J Selkoe
Apr 20, 1999·Biochemical and Biophysical Research Communications·Y M KuoA E Roher
Feb 9, 2002·Human Brain Mapping·Alexander HammersJohn Duncan
Jul 22, 2006·Lancet Neurology·Marieke van OijenMonique M B Breteler
Oct 17, 2008·Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition·Cheryl A LuisMichael Mullan
Jan 20, 2011·JAMA : the Journal of the American Medical Association·Kristine YaffeTamara B Harris
Sep 8, 2012·International Journal of Alzheimer's Disease·Pedro PesiniManuel Sarasa
Apr 2, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Shanker SwaminathanUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 14, 2014·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Naoki KanekoKoichi Tanaka
Jul 24, 2014·ACS Chemical Neuroscience·Kai-Yuan TzenMing-Jang Chiu
Sep 14, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Vincent ChourakiSudha Seshadri
Dec 3, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·William E KlunkMark A Mintun
Dec 9, 2014·Alzheimer's Research & Therapy·Oscar Sotolongo-GrauManuel Sarasa
Oct 8, 2015·Journal of Alzheimer's Disease : JAD·Hyeong Jun KimSun Ah Park
Nov 26, 2015·Journal of Alzheimer's Disease : JAD·Martina SattleckerRichard Jb Dobson
Jun 1, 2016·Scientific Reports·Shorena JanelidzeOskar Hansson
Aug 29, 2016·Journal of Alzheimer's Disease : JAD·Virginia Pérez-GrijalbaManuel Sarasa
Jan 11, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Hugo LövheimSture Eriksson
Jul 25, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Vitaliy OvodRandall J Bateman
Sep 28, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Noelia FandosUNKNOWN AIBL Research Group
Nov 22, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Shannon L RisacherAndrew J Saykin
Feb 20, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Olivier HanonUNKNOWN BALTAZAR study group
Apr 5, 2018·Journal of Alzheimer's Disease : JAD·Charlotte E TeunissenKaj Blennow
Apr 8, 2018·EMBO Molecular Medicine·Andreas NabersHermann Brenner
Jul 30, 2018·Alzheimer's Research & Therapy·Piotr LewczukHenrik Zetterberg
Sep 10, 2018·Annals of Neurology·Inge M W VerberkWiesje M van der Flier
Jan 23, 2019·Brain : a Journal of Neurology·Jong-Chan ParkInhee Mook-Jung

❮ Previous
Next ❯

Citations

Dec 8, 2019·The Journal of Applied Laboratory Medicine·Xuemei ZhaoOmar F Laterza
Dec 24, 2019·Journal of Alzheimer's Disease : JAD·Xiaoni WangYing Han
Sep 10, 2020·Frontiers in Genetics·Tao ZhangXiaoyang Mou
Sep 10, 2020·Journal of Personalized Medicine·Chiara ArgentatiSabata Martino
Oct 21, 2020·International Journal of Molecular Sciences·Cristina BarbagalloMarco Ragusa
Nov 21, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Lana FaniM Arfan Ikram
Dec 1, 2020·Journal of Alzheimer's Disease : JAD·Ivan KoychevHeinz Holling
Dec 2, 2020·Brain : a Journal of Neurology·Alexis MoscosoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jan 12, 2021·JAMA Neurology·Alexis MoscosoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Dec 16, 2019·Current Opinion in Neurobiology·Joel SimrénHenrik Zetterberg
Jan 8, 2021·Alzheimer's Research & Therapy·Jong-Chan ParkInhee Mook-Jung
Mar 31, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Rachel F Buckley
May 8, 2021·Scientific Reports·Elisabeth H ThijssenCharlotte E Teunissen
Jun 22, 2021·Journal of Alzheimer's Disease : JAD·Tzayaka Castillo-MendietaChristian Guerra-Araiza
Aug 7, 2021·Scientific Reports·Shibin ChengSurendra Sharma
Sep 2, 2021·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Shannon L RisacherUNKNOWN Alzheimer's Disease Neuroimaging Initiative#
Oct 7, 2021·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Giordana Salvi de SouzaAna Maria Marques da Silva

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay

Software Mentioned

Statistical Package for Social Sciences ( SPSS
SPM8
MarsBaR
FreeSurfer
Statistical Parametric Mapping 8 ( SPM8

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.